Abstract
Nowadays, the complexity of disease mechanisms and inadequacy of single-target therapies in restoring the biological system has inevitably instigated the strategy of multi-target therapeutics with the application of hybrid and chimeric drugs. However, the related method is still unable to solve the conflicts between targets or between drugs. With the release of high-precision protein structure prediction artificial intelligence (AI), large-scale high-precision protein structure prediction and docking become possible. In this article, we propose a multi-target drug discovery method. Then we take an example of therapeutic hypothermia (TH). We performed protein structure prediction for all targets of each group by AlphaFold2 and RoseTTAFold. QuickVina 2 is then used for molecular docking of the proteins and drugs. After docking, we use PageRank to get the rank of drugs and drug combinations of each group. Given the differences in the scoring of different proteins, the method can effectively avoid inhibiting beneficial proteins. So it’s friendly to chronopharmacology. This method also have potential in precision medicine for its high compatibility with bioinformatics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NO FUND.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# The first 1 author is the first author.
Declaration
Ethics approval and consent to participate. Not applicable.
Consent for publication All authors allow the publication of this article.
Availability of data and materials All the data that support the findings of this study are available for email from authors.
Competing interests The authors have declared that they have no conflicts or interests.
Funding The authors have stated that no such relationships exist.
Data Availability
